Amgen reported solid third-quarter results with increased earnings guidance and strong performance from growth products like Prolia and Repatha. Management's optimistic outlook on the biosimilars pipeline and continued capital returns to shareholders through dividends and buybacks are likely to bolster investor confidence in the short term.

[1]